GlassScriptPhysician profile
John Michael Rucker
NPI 1568462661
$12,549.14
in general payments reported to CMS, 2019-2025
48 companies · $2,920 in 2025
The $2,920 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $1,151 · 2021: $1,187 · 2022: $2,144 · 2023: $1,868 · 2024: $2,466 · 2025: $2,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,040 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,039.68 |
| Education | $213.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,104.74 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,380.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,017.80 | 2019-2025 | Ofev, Combivent Respimat, Jascayd |
| Genzyme Corporation | $755.25 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $717.67 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $714.86 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $624.91 | 2021-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $550.60 | 2019-2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $443.38 | 2020-2025 | Glassia, Hyqvia, Cuvitru |
| Amgen INC. | $387.09 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $383.32 | 2019-2023 | Xolair |
| Grifols USA, LLC | $372.51 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Mylan Specialty L.P. | $315.39 | 2019-2024 | Yupelri |
| Csl Behring | $248.29 | 2019-2025 | Hizentra |
| Verona Pharma, INC. | $247.29 | 2025 | Ohtuvayre |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.